Idera Pharmaceuticals, Inc. (IDRA) Announces Achievement of Clinical Milestone Under Its Collaboration with Merck KGaA (MKGAF.PK) for Cancer Treatment 1/19/2010
More...
|
Henry Ford Hospital Study Finds 231 New Genes Associated With Head And Neck Cancer 10/5/2009
More...
|
Curcumin May Inhibit Nicotine-induced Activation Of Head And Neck Cancers, Study Presented At American Academy of Otolaryngology Conference 10/5/2009
More...
|
World’s First IsoRay, Inc. (ISR)'s Cesium-131 Implant For Recurrent Head And Neck Cancer Performed At Weill Cornell Medical College 9/28/2009
More...
|
Access Pharmaceuticals (ACCP) Release: MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 7/23/2009
More...
|
Genmab A/S (GNMSF.PK) Announces Lift of Zalutumumab Partial Clinical Hold 7/17/2009
More...
|
Robotic Surgery Practical for Some Head, Neck Tumors, University of Alabama at Birmingham Study 4/21/2009
More...
|
FDA Seeks More Data for Eli Lilly and Company (LLY)'s (JOBS) Erbitux for Head and Neck Cancer 3/3/2009
More...
|
Viralytics Ltd to Test CAVATAK(TM) in Head and Neck Cancer 12/9/2008
More...
|
Oral Rinses Used For Tracking HPV-Positive Head And Neck Cancers Holds Promise For Cancer Screening, Johns Hopkins University Study 10/31/2008
More...
|
Merck KGaA (MKGAF.PK)'s Erbitux Gets Green Light for Head Cancer 10/24/2008
More...
|
Chest CT Scans Detect Spread of Head, Neck Cancers, Taipei Veterans General Hospital Study 10/22/2008
More...
|
SensiGen LLC HPV Assay Enables Major Breakthrough in Diagnosis and Treatment of Head and Neck Cancer 9/25/2008
More...
|
Bristol-Myers Squibb Company (BMY) (JOBS), ImClone Systems Incorporated (IMCL) (JOBS) Drug Aids Head/Neck Cancer Survival 9/23/2008
More...
|
University of Pennsylvania School of Medicine Researchers Identify Natural Tumor Suppressor 9/11/2008
More...
|
ImClone Systems Incorporated (IMCL) and Bristol-Myers Squibb Company (BMY) Erbitux Extends Head, Neck Cancer Survival in Study Conducted by Merck KGaA (MKGAF.PK) in Germany 9/11/2008
More...
|
ImClone Systems Incorporated (IMCL) Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer 9/3/2008
More...
|
Azaya Therapeutics, Inc. Licenses Promising Treatment for Head and Neck Cancers 9/3/2008
More...
|
Introgen Therapeutics, Inc. (INGN) Release: ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate in Prospectively Defined Biomarker Patient Population 7/23/2008
More...
|
IRX Therapeutics Announces Results of Phase 2 Study for IRX-2 7/22/2008
More...
|
Introgen Therapeutics, Inc. (INGN)'s Flagship Cancer Drug Advexin Questioned 7/15/2008
More...
|
IRX Therapeutics to Present Phase 2 Results at 7th International Conference on Head and Neck Cancer 7/15/2008
More...
|
Introgen Therapeutics, Inc. (INGN) Seeks FDA (JOBS) Approval for 'Groundbreaking' Cancer Drug 7/1/2008
More...
|
Genmab A/S (GNMSF.PK) Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 6/25/2008
More...
|
CEL-SCI (CVM) Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 6/4/2008
More...
|
GenVec Inc. (GNVC) Release: Encouraging Findings from TNFerade™ Head and Neck Cancer Study Presented at American Society of Clinical Oncology 6/2/2008
More...
|
Introgen Therapeutics, Inc. (INGN) Release: ADVEXIN(R) Pivotal Phase III Data Presented as Part of Late-Breaking American Society of Gene Therapy Presentation 5/30/2008
More...
|
Mary Crowley Cancer Research Centers and Introgen Therapeutics, Inc. (INGN) Release: Groundbreaking Clinical Trial at Mary Crowley Significantly Increases Survival in End-Stage Head and Neck Cancer Patients 5/29/2008
More...
|
Cellceutix Cancer Compound: Crunching the Numbers 5/29/2008
More...
|
PET Imaging May Not Improve Diagnostic Accuracy In Early Head And Neck Cancer, University of Ioannina School of Medicine Study 5/20/2008
More...
|
Tooth Loss Strongly Linked To Risk Of Esophageal, Head And Neck, And Lung Cancer, Aichi Cancer Center and Nagoya University Study 5/14/2008
More...
|
Cellceutix Obtains Initial Funding to Advance Its Head and Neck Cancer Drug 5/14/2008
More...
|
New Surgery Improves Head And Neck Cancer Treatment, University of Alabama at Birmingham 5/2/2008
More...
|
New Surgery Improves Head & Neck Cancer Treatment 4/30/2008
More...
|
Melanoma's Site May Determine Survival; Study Shows Neck, Scalp Melanoma Have Worst Survival Outcomes 4/22/2008
More...
|
ImClone Systems Incorporated (IMCL) Release: Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment 4/9/2008
More...
|
Oncolytics Biotech Inc. (ONC.TO) Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 4/9/2008
More...
|
Introgen Therapeutics, Inc. (INGN) Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008 12/20/2007
More...
|
ImClone Systems Incorporated (IMCL) 1000TH Patient Enrolls in National ``LORHAN'' Head and Neck Cancer Registry 10/29/2007
More...
|
Fruit Compound Fights Head and Neck Cancer 10/16/2007
More...
|
Sanofi-Aventis (France) (SASY.PA) Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 10/1/2007
More...
|
Introgen Therapeutics, Inc. (INGN) Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers 9/27/2007
More...
|
Danish Head and Neck Cancer Group Initiates Study With Genmab A/S (GNMSF.PK)'s HuMax-EGFr 9/13/2007
More...
|
High Rate of Head-and-Neck Cancer in Women Pinned to Smoking 8/28/2007
More...
|
Oral Sex Implicated in Some Throat and Neck Cancers; Suggests Boys Need Merck & Co., Inc. (MRK) (Jobs) Vaccine 8/28/2007
More...
|
A New Radiation Therapy Treatment Developed for Head and Neck Cancer Patients in Phase I/II study 8/17/2007
More...
|
Oregon Health & Science University (OHSU) Cancer Institute Researchers Get Closer To Predicting Head, Neck Cancer Patients' Survivability 6/28/2007
More...
|
Sanofi-Aventis (France) (SASY.PA) Release: Taxotere(R) (docetaxel) Granted FDA Priority Review 6/27/2007
More...
|
Inovio Biomedical Corporation (INO) Stops Enrollment of Phase III Clinical Trials for Head & Neck Cancer 6/5/2007
More...
|
Introgen Therapeutics, Inc. (INGN) Reports Updated Phase 2 ADVEXIN(R) Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker 6/4/2007
More...
|
CEL-SCI (CVM) Presents Long-Term Cancer Survival Data With Multikine(R) 5/21/2007
More...
|
ImClone Systems Incorporated (IMCL) (Jobs) Erbitux Cancer Drug Rebuffed Again by UK's NICE 5/16/2007
More...
|
Introgen Therapeutics, Inc. (INGN) Initiates Efficacy Analyses of ADVEXIN Phase 3 Clinical Trial Data for Head and Neck Cancer 4/24/2007
More...
|
University of Pittsburgh's New Approach to Vaccine for Head and Neck Cancer Creates Immune Response by Targeting Proteins 4/18/2007
More...
|
ImClone Systems Incorporated (IMCL) (Jobs) Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer 4/4/2007
More...
|
ImClone Systems Incorporated (IMCL): Survival Data Available from ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer 4/4/2007
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150 3/22/2007
More...
|
GlaxoSmithKline (GSK) Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer 2/26/2007
More...
|
Amgen (AMGN)'s (Jobs) New Aranesp Safety Concerns Seen In Cancer Trial 2/19/2007
More...
|
Inovio Biomedical Corporation Presents MedPulser(R) Electrochemical Tumor Ablation Results At 5th International Symposium On Advances In Head & Neck Cancer 2/1/2007
More...
|
GenVec Inc. (GNVC) Announces First Patient Treated With TNFerade(TM) For Head And Neck Cancer At University of Chicago 1/26/2007
More...
|
Blood Test: Weizmann Institute of Science Scientists Discover A Genetic Risk Factor For Smoking-Linked Head And Neck Cancer 1/25/2007
More...
|
Cetuximab May Prolong Survival For Head And Neck Cancer Patients 1/19/2007
More...
|
New Screening Process Helps Better Diagnose Oral Cancers 1/19/2007
More...
|
Stem Cell Marker Identified In Head And Neck Cancer 1/17/2007
More...
|
Introgen Therapeutics, Inc. (INGN) Announces Conference Call; Phase 3 Trial Analysis Plans And New Clinical Data To Be Discussed 12/28/2006
More...
|
European Organization for Research and Treatment of Cancer And FDA Extend Drug-Label Based On Results Of The European Medicines Evaluation Agency 24971 Trial 10/20/2006
More...
|
Sanofi-Aventis (France) (SASY.PA) Release: Taxotere(R) Receives U.S. FDA Approval For The Treatment Of Patients With Head And Neck Cancer 10/18/2006
More...
|
Cytokinetics, Inc. (CYTK) Reports Data For Ispinesib In Recurrent And/Or Metastatic Head And Neck Squamous Cell Carcinoma; Drug Fails Trial 10/3/2006
More...
|
Cordis Corporation (JNJ) Release: FDA Approves New Medical Devices To Treat Clogged Neck Arteries 9/26/2006
More...
|
Advaxis, Inc. Meets With FDA Regarding Phase II Of Lovaxin C 9/25/2006
More...
|
Genmab A/S (GNMSF.PK) Initiates HuMax-EGFr Pivotal Study In Refractory Head And Neck Cancer 9/14/2006
More...
|
Introgen Therapeutics, Inc. (INGN) Presents Biomarker Data Predictive Of Therapeutic Efficacy At Annual Meeting Of The American Head And Neck Society 8/21/2006
More...
|
YM BioSciences (YM.TO) Reports Anti-EGFr Drug Nimotuzumab Approved In India For Treatment Of Head And Neck Cancer 7/21/2006
More...
|
Panel of Experts To Review Importance Of Introgen Therapeutics, Inc. (INGN)'s Recently Reported ADVEXIN Data 6/26/2006
More...
|
Intraop Medical, Inc. Release: IOERT Shown To Be Highly Effective In Treating Locally Advanced Head And Neck Cancer 6/13/2006
More...
|
Increased Survival And High Response Rates Reported For Introgen Therapeutics, Inc. (INGN)'s ADVEXIN p53 Therapy 6/5/2006
More...
|
Oregon Health & Science University (OHSU) Researcher Develops First Animal Model To Treat Devasting Head And Neck Cancers 5/15/2006
More...
|
CEL-SCI (CVM) Release: Cancer Survival Data From Multikine To Be Presented In May 2006 5/10/2006
More...
|
ImClone Systems Incorporated (IMCL) Issues Statement Regarding European Commission Approval For ERBITUX(R) For The Treatment Of Head And Neck Cancer 4/3/2006
More...
|
Recent FDA Action Validates ADVEXIN(R) Registration Strategy; Introgen Therapeutics, Inc. (INGN) Encouraged By Approval Of Erbitux(R) For Head And Neck Cancer 3/3/2006
More...
|
ImClone Systems Incorporated (IMCL) And Bristol-Myers Squibb Company (BMY) Release: FDA Approves ERBITUX(R) For Treatment Of Head And Neck Cancer; First And Only Approved Monoclonal Antibody For Squamous Cell Carcinoma Of The Head And Neck 3/2/2006
More...
|
ImClone Systems Incorporated (IMCL) Issues Statement Regarding Positive Opinion From CHMP For Use Of ERBITUX(R) In Head And Neck Cancer 2/23/2006
More...
|
ImClone Systems Incorporated (IMCL) Announces Complete Enrollment Of Several Studies Examining Potential Survival Benefit Of ERBITUX(R) In Three Major Cancer Types 2/16/2006
More...
|
BioVex Begins Dosing Patients In Phase II Clinical Trials Of OncoVEXGMCSF In Malignant Melanoma And In Head And Neck Cancer 2/14/2006
More...
|
Genmab A/S (GNMSF.PK)'s HuMax-EGFr Awarded Fast Track Status From FDA 1/3/2006
More...
|
ImClone Systems Incorporated (IMCL) Issues Statement Regarding Swissmedic Approval Of ERBITUX For The Treatment Of Head And Neck Cancer 12/22/2005
More...
|
Introgen Therapeutics, Inc. (INGN) Updates Regulatory Guidance For ADVEXIN Therapy Of Head And Neck Cancer 12/22/2005
More...
|
Shanghai Sunway Biotech Co. Ltd. Release: First Oncolytic Viral Therapy Approved For Head And Neck Cancer 11/17/2005
More...
|
ImClone Systems Incorporated (IMCL)'s ERBITUX(R) Data On Locoregional Control And Overall Survival In Phase III; Drug Extends Life In Head, Neck Cancer Patients 11/16/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Receives Fast Track Designation From The FDA For Proxinium(TM) In Head & Neck Cancer 11/11/2005
More...
|
ImClone Systems Incorporated (IMCL) And Bristol-Myers Squibb Company (BMY) Release: FDA Accepts ERBITUX(R) (Cetuximab) sBLA Submission For The Treatment Of Squamous Cell Carcinoma Of The Head And Neck And Grants Priority Review 10/31/2005
More...
|
IRX Therapeutics Enrolls First Patients In IRX-2 Phase II Head And Neck Cancer Study 10/17/2005
More...
|
Lannett Company, Inc. (LCI) Receives Approval For Pilocarpine HCL 10/17/2005
More...
|
Inovio Biomedical Corporation (INO) Study Results Of Gene-Based Therapies For HIV And Vascular Disease Published In Scientific Journals 10/13/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Provides Update Of Vicinium(TM) Clinical Program 10/7/2005
More...
|
Common Gene Variant May Help Spur Cancer 10/5/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Receives Health Canada Clearance To Initiate Phase II Cancer trial Tor Proxinium(TM) 10/5/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Receives FDA Clearance To Initiate Phase II Cancer Trial For Proxinium(TM) 9/19/2005
More...
|
ImClone Systems Incorporated (IMCL) And Bristol-Myers Squibb Company (BMY) File Supplemental Biologics License Application For ERBITUX(R) For Treatment Of Head And Neck Cancer 8/30/2005
More...
|
Advaxis, Inc. Release Of Clinical GMP Materials For Phase I/II In Cervical Cancer 8/8/2005
More...
|
Cottonseed Drug May Help In Head, Neck Cancer 7/22/2005
More...
|
Compound From Chinese Medicine Shows Promise In Head And Neck Cancer 7/19/2005
More...
|
ImClone Systems Incorporated (IMCL) To File sBLA For Use Of Erbitux In Head And Neck Cancer In Third Quarter 2005 6/20/2005
More...
|
ImClone Systems Incorporated (IMCL) Release: Independent Clinical Review Of Phase III Trial Shows Erbitux And Radiation Control Spread Of Advanced Squamous Cell Cancer Of The Head And Neck Better Than Radiation Alone; Primary And Secondary Study Endpoints Met With Statistical Significance; Shares Up 6/8/2005
More...
|
Viventia Biotech Inc.'s (VBI.TO) Proxinium(TM) Receives EU Orphan Drug Designation 6/1/2005
More...
|
BioAlliance Pharma Presents Results From Phase III Study Of Miconazole Lauriad Bioadhesive Buccal Tablets For Treatment Of Oropharyngeal Candidiasis In Head & Neck Cancer Patients 5/17/2005
More...
|
Investigators Present Results Of New Lung Cancer Research With Ligand Pharmaceuticals Inc. (LGND) Therapies At American Society of Clinical Oncology 5/17/2005
More...
|
ImClone Systems Incorporated (IMCL) , Bristol-Myers Squibb Company (BMY) Release Positive Erbitux Data For Variety Of Cancers 5/16/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Presents Proxinium(TM) Posters At American Society of Clinical Oncology 5/16/2005
More...
|
Genmab A/S (GNMSF.PK) Presents Additional HuMax(R)-EGFr Phase I/II Efficacy Data At American Society of Clinical Oncology Conference 5/13/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Reports First Quarter 2005 Results 5/12/2005
More...
|
YM BioSciences (YM.TO) Completes Acquisition Of Delex Therapeutics Inc. 5/3/2005
More...
|
Point Therapeutics Reports Additional Preclinical Data Demonstrating Anti-Tumor Activity Of Talabostat 4/18/2005
More...
|
ImClone Systems Incorporated (IMCL) , Bristol-Myers Squibb Company (BMY) Delay Plan For Erbitux Filing 4/13/2005
More...
|
Merck KGaA (MKGAF.PK) Still Plans To Submit Application For Approval Of Erbitux Mid-2005 4/13/2005
More...
|
Vitamin E May Harm Patients With Head, Neck Cancers 4/6/2005
More...
|
Incyte Corporation (INCY) Begins Phase I Study In Healthy Volunteers Of Novel Oral Cancer Compound, INCB7839 4/6/2005
More...
|
Cytokinetics, Inc. (CYTK) Announces Interim Phase I Results For SB-743921 To Be Presented At The 2005 Annual Meeting Of The American Society of Clinical Oncology 4/6/2005
More...
|
Company Profile For Inovio Biomedical Corporation 4/4/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Reports Positive Head & Neck Cancer Results 3/29/2005
More...
|
FDA Grants Viventia Biotech Inc. (VBI.TO) Orphan Drug Designation For Proxinium(TM) 2/4/2005
More...
|
Northwest Biotherapeutics (NWBT) To Initiate Phase III Clinical Trial For Prostate Cancer 2/1/2005
More...
|
Viventia Biotech Inc. (VBI.TO) Completes Enrolment Of Second Proxinium (TM) Clinical Trial 1/25/2005
More...
|
EntreMed, Inc. (ENMD) Release: Report Demonstrates Activity Of 2ME2 With Paclitaxel In Head And Neck Carcinoma 1/19/2005
More...
|
H. Lee Moffitt Cancer Center & Research Institute And Genetronics Biomedical (GEB) Initiate Phase I Clinical Trial In Patients With Malignant Melanoma 1/13/2005
More...
|
Gene Profiling May Improve Treatment Of Head And Neck Cancer 1/10/2005
More...
|
Diatos S.A. Acquires Oncology Product Rights From MacroMed, Inc. 1/6/2005
More...
|
Diatos S.A. Acquires Oncology Product Rights From MacroMed, Inc. 1/5/2005
More...
|
BioAlliance Pharma Announces Preliminary Phase III Data On Miconazole Lauriad Bioadhesive Buccal Tablets For Local Treatment Of Oropharyngeal Candidiasis In Head And Neck Cancer Patients Following Radiation Therapy 1/4/2005
More...
|
Introgen Therapeutics, Inc. (INGN) Announces New Clinical Data For ADVEXIN And Submits Request To FDA For Initiation Of Accelerated Approval Biologics License Application 12/23/2004
More...
|
Introgen Therapeutics, Inc.'s (INGN) ADVEXIN Cancer Therapy Receives Additional Protection With Issuance Of Patent 12/20/2004
More...
|
Stressgen Biotechnologies Corporation (SSB.TO) Completes Enrollment In HspE7 Internal Genital Warts Trial 12/2/2004
More...
|
Genmab A/S (GNMSF.PK) Announces Encouraging Efficacy Data From HuMax-EGFr Phase I/II Trial In Head And Neck Cancer 12/1/2004
More...
|
Viventia Biotech Inc. (VBI.TO) Release: Proxinium(TM) Demonstrates Positive Clinical Responses In Head And Neck Cancer Clinical Trial 10/28/2004
More...
|
Betel Nut Tied To Head, Neck Cancers 10/21/2004
More...
|
Genomic Factors Augment TNM Staging In Squamous Cell Head And Neck Cancer 10/19/2004
More...
|
Genmab A/S (GNMSF.PK) Announces Positive Phase I/II HuMax{TM}-EGFr Safety Data 10/4/2004
More...
|
Genetronics Biomedical (GEB) Release: Studies Suggest Alternatives To Surgery Are Needed In Treatment Of Head And Neck Cancer 9/15/2004
More...
|
Submandibular Gland Transfer Prevents Radiation-induced Xerostomia 9/14/2004
More...
|
CEL-SCI (CVM) Release: Multikine(R) Cancer Drug Lowers Cholesterol In Clinical Studies 9/9/2004
More...
|
Erimos Pharmaceuticals Presents Positive Safety And Preliminary Efficacy Results From A Phase I Clinical Trial Of EM-1421 In Refractory Cancer Patients At The 6th International Conference On Head And Neck Cancer 8/13/2004
More...
|
Introgen Therapeutics, Inc. (INGN) Phase 2 ADVEXIN(R) Data Presented At 6th International Head And Neck Cancer Conference 8/10/2004
More...
|
Merck KGaA-Plans (MKGAF.PK) To file Erbitux For head, Neck Cancer 7/27/2004
More...
|
ImClone Systems Incorporated (IMCL) And Bristol-Myers Squibb Company (BMY) To Seek Erbitux OK For Head, Neck Cancer 7/21/2004
More...
|
Adherex Technologies Inc. (CT:AHX) Obtains Investigational New Drug "IND" Clearance From U.S. FDA For Exherin(TM) 7/6/2004
More...
|
PharmaMar S.A. Release: FDA Grants IND For Aplidin To Enter Phase II Trials In U.S. 6/22/2004
More...
|
Introgen Therapeutics, Inc. (INGN) Reports Broad Utility Of Lead Product ADVEXIN(R) At ASCO Symposium 6/9/2004
More...
|
Merck KGaA (MKGAF.PK) , ImClone Systems Incorporated (IMCL) And Bristol-Myers Squibb Company (BMY) Scientific Data Presented At ASCO Annual Meeting Evaluating ERBITUX(TM) (Cetuximab) In Head And Neck Cancer (Abstracts 5502 And 5513) 6/8/2004
More...
|
ImClone Systems Incorporated, (IMCL) Merck KGaA, (MKGAF.PK) And Bristol-Myers Squibb Company (BMY) Relesae: Phase III Study Of Erbitux (Cetuximab) And High-Dose Radiation In Locally Advanced Head And Neck Cancer At American Society of Clinical Oncology (Abstract 5507) 6/7/2004
More...
|
Aventis Pharmaceuticals, Inc. (AVE) Release: Investigators Report Taxotere Offers Significant Survival Benefits For Head And Neck Cancer Patients 6/7/2004
More...
|
European Organization for Research and Treatment of Cancer Release: Investigators Report Taxotere Offers Significant Survival Benefits For Head And Neck Cancer Patients 6/7/2004
More...
|
MedImmune (MEDI) Release: Data Show Ethyol Reduces Radiation Therapy-Induced Dry Mouth In Head And Neck Cancer Patients For 24 Months 6/7/2004
More...
|
CEL-SCI (CVM) Publishes Phase II Clinical Trial Results At American Society of Clinical Oncology 6/7/2004
More...
|
Genetronics (GEB) Granted FDA Fast Track Designation For Its MedPulser(R) Electroporation Therapy System For Head And Neck Cancer 6/7/2004
More...
|
YM BioSciences' (LS:YMB) Cancer Antibody Subject Of Journal Publication 5/12/2004
More...
|
Introgen Therapeutics, Inc. (INGN) To Present Advexin And INGN 241 Data At Annual Meeting Of The American Association For Cancer Research 3/23/2004
More...
|
U.S. FDA Looks At Anemia Drugs, Cancer Risks 3/19/2004
More...
|
CEL-SCI (CVM) Abstract Selected For Publication In The American Society of Clinical Oncology Proceedings 3/11/2004
More...
|
Pregnancy Disorder Link To Cancer 3/5/2004
More...
|
Genetronics (GEB) Starts European Clinical Study For Primary And Recurrent Head And Neck Cancer To Advance Commercialization Of The MedPulser 3/1/2004
More...
|
Pharmacyclics (PCYC) Announces The Presentation Of Updated Interim Phase 1 Clinical Data With Xcytrin And Concurrent Chemoradiation For Advanced Head And Neck Cancer 3/1/2004
More...
|
Blood Test For Head And Neck Cancers 2/25/2004
More...
|
Genetronics (GEB) Completes FDA Special Protocol Assessment (SPA) Process, Begins Patient Enrollment In Phase III Recurrent Head And Neck Cancer Studies 2/24/2004
More...
|
Genetronics Biomedical (GEB) Completes FDA Special Protocol Assessment (SPA) Process, Begins Patient Enrollment In Phase III Recurrent Head And Neck Cancer Studies 2/23/2004
More...
|
DakoCytomation Receives FDA Approval For EGFR pharmDx(TM) 2/16/2004
More...
|
Vion Pharmaceuticals (VION) Provides Update On Clinical Trials Of Triapine(R) As A Single Agent; Company Ends Separate Phase II Trial For Prostate Cancer To Focus Studies On Other Trianpine Trials 2/6/2004
More...
|
Genmab A/S (DK:GEN) Announces Year End 2003 Financial Results 2/5/2004
More...
|
Pharmacyclics (PCYC) Reports Second Quarter Financial Results 1/29/2004
More...
|
Hi-Tech Tool Offers Breakthrough Cancer Treatment 1/26/2004
More...
|
Keryx Biopharmaceuticals (KERX) Adds Three Clinical-Stage Oncology Drug Candidates To Its Pipeline, Including A Novel, First-In-Class, Oral AKT-Inhibitor In Phase II 1/8/2004
More...
|
M. D. Anderson Cancer Center Orlando Among First To Fight Cancer With TomoTherapy's Helical Tomotherapy In United States 1/6/2004
More...
|
Virus Linked To Type Of Head And Neck Cancer 12/12/2003
More...
|
New Clue To Breast Cancer Mortality 12/8/2003
More...
|
CEL-SCI's (CVM) Study Demonstrates Multikine(R) Makes Tumor Cells Highly Susceptible To Radiation Therapy 12/8/2003
More...
|
Genetronics (GEB) And Chiron Corporation (CHIR) Extend Collaborative Agreement On Technology For HIV Vaccine Delivery 12/2/2003
More...
|
Medarex, Inc. (MEDX) Announces Phase I/II Clinical Trial Development Of MDX-214 For The Treatment Of EGF-R Overexpressing Cancers 11/24/2003
More...
|
Pharmacyclics (PCYC) Announces The Presentation Of Interim Phase 1 Clinical Data With Xcytrin And Concurrent Chemoradiation For Advanced Head And Neck Cancer 11/13/2003
More...
|
New Brunswick Scientific (NBSC) Release: The World's First Commercially-Licensed Gene Therapy Drug Produced In NBS CelliGen Plus(R) Packed-Bed Bioreactor 11/6/2003
More...
|